Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments
- Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million
- Angelini Pharma will become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments
- Opening direct affiliates in France, UK, Nordics and Switzerland by 2022
News provided by
Share this article
ROME, Jan. 14, 2021 /PRNewswire/
Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and